Therefore, we propose that FH may regulate sensitivity to treatment with PD-1 antibodies in patients with CRC and that patients with CRC with low FH expression may benefit from combined treatment with PCSK9 inhibitors and PD-1 antibodies. Here, PDCD1 is linked to colorectal carcinoma.